Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2031-2042

  Herter, Sylvia ^a   Herting, Frank ^b   Mundigl, Olaf ^b   Waldhauer, Inja ^a   Weinzierl, Tina ^a   Fauti, Tanja ^a   Muth, Gunter ^b   Ziegler Landesberger, Doris ^b   Puijenbroek, Erwin Van ^a   Lang, Sabine ^a   Duong, Minh Ngoc ^c   Reslan, Lina ^c   Gerdes, Christian A ^a   Friess, Thomas ^b   Baer, Ute ^b   Burtscher, Helmut ^b   Weidner, Michael ^b   Dumontet, Charles ^c   Umana, Pablo ^a   Niederfellner, Gerhard ^b   Bacac, Marina ^a   Klein, Christian ^a   more..

^a Roche Glycart AG   (Switzerland)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C1Q; LIPOCORTIN 5; OBINUTUZUMAB; OFATUMUMAB; PROPIDIUM IODIDE; RITUXIMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELL MEDIATED PHAGOCYTOSIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER CONTROL; CANCER MODEL; CANCER REGRESSION; CELL DEATH; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; TIME LAPSE IMAGING; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; APOPTOSIS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MICE; NEOPLASMS; PHAGOCYTOSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885671483     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1182     Document Type: Article

References (40)

1. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineeringofa newtypeIIanti-CD20antibodywithenhanceddirectandimmune effector cell-mediated B-cell cytotoxicity. Blood 2010;115: 4393-402.
2. Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011;108: 12669-74.
3. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115: 5191-201.
4. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119: 2143-59.
5. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011;118: 358-67.
6. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117: 4519-29.
7. Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012;119: 3523-33.
8. Gravanis I, Ersboll J, Skovlund E, Abadie E, Marty M, Pignatti F. The European Medicines Agency review of ofatumumab (Arzerra(R)) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. Oncologist 2010;15: 1335-43.
9. Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010;16: 4331-8.
10. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183: 749-58.
11. Engelberts J, Beurskens F, Mackus W, Bakker J, Vink T, Tiebout A, et al. Ofatumumab targets a conformational membrane-proximal epitope which contains amino acids located in the small and large loops of CD20. Haematol-Hematol J 2010;95:46-.
12. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177: 362-71.
13. Golay J, Bologna L, Andre PA, Buchegger F, Mach JP, Boumsell L, et al. Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood 2010;116: 3372-3.
14. Cragg MS, Alduaij W, Klein C, Umana P, Glennie MJ, Illidge TM. Novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates Response. Blood 2010;116: 3373-4.
15. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011;118: 2530-40.
16. Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, et al. Preclinical studies on the mechanism of action and the antilymphoma activity of the novel anti-CD20 antibody GA101.Mol Cancer Ther 2011;10: 178-85.
17. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26: 4579-86.
18. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116: 2040-5.
19. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet 2010;376: 1164-74.
20. Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V, et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 2012;26: 546-9.
21. Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of Bcell malignancies. Blood 2011;118: 4159-68.
22. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103: 2738-43.
23. Kishore U, Reid KB. C1q: structure, function, and receptors. Immunopharmacology 2000;49: 159-70.
24. Taylor RP, Pawluczkowycz AW, Beum PV, Lindorfer MA, Beurskens F, van de Winkel J, et al. Complement activation and comlement-mediated killing of B cells promoted by anti-CD20 monoclonal antibodies (mAb) rituximab and ofatumumab are rapid, and ofatumumab kills cells more rapidly and with greater efficacy. Blood 2007;110:695a-a.
25. Beurskens J, Mackus W, Engelberts P, Miller S, Speller S, Chamberlain L, et al. NK cell binding and induction of potent NK cell-mediated ADCC by ofatumumab, a new human CD20 monoclonal antibody [abstract]. Haematologica 2010;95(Suppl 2):173. Abstract nr 0426.
26. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104: 1793-800.
27. Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010;59: 1197-209.
28. Nishida M, Teshigawara K, Niwa O, Usuda S, Nakamura T, Ralph P, et al. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions. Int J Oncol 2008;32: 1263-74.
29. Uchiyama S, Suzuki Y, Otake K, Yokoyama M, Ohta M, Aikawa S, et al. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci 2010;101: 201-9.
30. Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013;190: 231-9.
31. Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 2013;190: 2702-11.
32. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008;111: 1456-63.
33. Kern DJ, James BR, Blackwell S, Gassner C, Klein C, Weiner GJ. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma. Epub 2013 Apr 16.
34. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012;188: 3532-41.
35. Patz M, Isaeva P, Forcob N, Muller B, Frenzel LP, Wendtner CM, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011;152: 295-306.
36. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186: 3762-9.
37. Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012;119: 5118-25.
38. Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012;119: 5126-32.
39. Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol 2012;156: 490-8.
40. Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011;96: 1822-30.